Ocular Therapeutix Inc [OCUL] stock is trading at $11.91, up 3.39%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The OCUL shares have gain 7.88% over the last week, with a monthly amount drifted -6.66%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ocular Therapeutix Inc [NASDAQ: OCUL] stock has seen the most recent analyst activity on September 15, 2025, when Chardan Capital Markets initiated its Buy rating and assigned the stock a price target of $21. On March 18, 2025, RBC Capital Mkts initiated with a Outperform rating and assigned a price target of $17 on the stock. Needham started tracking the stock assigning a Buy rating and suggested a price target of $15 on March 11, 2025. Scotiabank initiated its recommendation with a Sector Outperform. TD Cowen upgraded its rating to Buy for this stock on June 20, 2024, and upped its price target to $11.
Ocular Therapeutix Inc [OCUL] stock has fluctuated between $5.78 and $13.85 over the past year. Currently, Wall Street analysts expect the stock to reach $25.75 within the next 12 months. Ocular Therapeutix Inc [NASDAQ: OCUL] shares were valued at $11.91 at the most recent close of the market. An investor can expect a potential return of 116.2% based on the average OCUL price forecast.
Analyzing the OCUL fundamentals
Ocular Therapeutix Inc [NASDAQ:OCUL] reported sales of 56.66M for the trailing twelve months, which represents a drop of -18.14%. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -4.03%, Pretax Profit Margin comes in at -3.83%, and Net Profit Margin reading is -3.83%. To continue investigating profitability, this company’s Return on Assets is posted at -0.48, Equity is -0.7 and Total Capital is -0.56. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.47 points at the first support level, and at 11.03 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.44, and for the 2nd resistance point, it is at 12.98.
Ratios To Look Out For
For context, Ocular Therapeutix Inc’s Current Ratio is 10.09. Also, the Quick Ratio is 10.02, while the Cash Ratio stands at 9.11. Considering the valuation of this stock, the price to sales ratio is 44.54, the price to book ratio is 6.73.
Transactions by insiders
Recent insider trading involved TODD ANDERMAN, Officer, that happened on Oct 08 ’25 when 11132.0 shares were purchased. Chief Development Officer, Kaiser Peter completed a deal on Oct 02 ’25 to sell 9653.0 shares. Meanwhile, Chief Scientific Officer Heier Jeffrey S. sold 10502.0 shares on Oct 02 ’25.
